Although it does not exhibit discernable cardiac toxicity, the new ALK5 inhibitor galunisertib produced only modest therapeutic responses in pancreatic cancer and HCC in phase II trials40–42. The gene discussed is TGFBR1; the disease is pancreatic neoplasm.